ADELA
adelabio.com
Actively hiring
Medical Laboratories
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Abstract TPS10628
At the ASCO Annual Meeting, Adela is also presenting data using an updated classifier for recurrence detection for head & neck squamous cell carcinoma. Adela previously reported clinical validation results for head & neck cancer in Annals of Oncology.
Read more
Report
Abstract 6084:
At the ASCO Annual Meeting, Adela is also presenting data using an updated classifier for recurrence detection for head & neck squamous cell carcinoma. Adela previously reported clinical validation results for head & neck cancer in Annals of Oncology.
Read more
Report
Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab
Immunotherapy has significantly improved the treatment of metastatic solid tumors; however, detecting early signs of response to enable timely intervention for resistant tumors remains challenging. A blood-only circulating tumor DNA (ctDNA) test may provi
Read more
Report
Report
Report
Annals of Oncology )
Adela is developing best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Adela's blood-based, tissue-free produ
Read more
Report